Enliven Therapeutics Inc., a clinical-stage biopharmaceutical company, has released its financial results for the second quarter of 2025. The company reported a net loss of $25.3 million for the quarter, an increase from the $20.0 million net loss reported in the same period of 2024. Research and development expenses for the quarter rose to $21.5 million, up from $18.8 million in the prior year's second quarter. General and administrative expenses also increased to $7.1 million from $5.8 million in the second quarter of 2024. Enliven highlighted positive data from the Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia $(CML.UK)$, with a cumulative major molecular response $(MMR.AU)$ rate of 47% and 32% of patients achieving MMR by 24 weeks. The company reported that ELVN-001 demonstrated a favorable safety and tolerability profile across all dose levels. The company maintains a strong balance sheet with $491 million in cash, cash equivalents, and marketable securities, which is expected to sustain operations into the first half of 2029. Looking ahead, Enliven plans to initiate its first Phase 3 pivotal trial of ELVN-001 in 2026, building on the positive clinical data reported. The company also strengthened its financial position through a recent public offering, generating approximately $230 million in gross proceeds.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.